【摘要】 目的:评价雷帕霉索洗脱支架(Cypher^TM)和紫杉醇涂层支架(Taxus^TM)治疗冠心病（CAD）合并2型糖尿病（DM）患者短期疗效和安全性。方法:从2002年12月至2006年3月共116例合并CAD和DM的患者入选本研究,共植入药物涂层支架186个（雷帕霉素洗脱支架97个,紫杉醇涂层支架89个）。观察6个月的主要心血管不良事件（MACE）。结果:接受两种支架植入的患者基本临床特征相似。支架植入成功率100%,95%的患者完成了6个月的随访。雷帕霉素洗脱支架组总的MACE事件发生率约为6．78%（4/59）,紫杉醇涂层支架组总的MACE事件发生率约为7．02%（4/57）,两组相比无统计学差异。结论:雷帕霉素洗脱支架和紫杉醇涂层支架治疗CAD合并2型DM的患者有相似的疗效。更多还原

【Abstract】 Objective:To compare the short-term clinical outcomes of rapamycin（sirolimas）eluting stent(CYPHER^TM)and paclitaxel eluting stent(Taxus^TM)in treatment of coronary coronary disease patients with type 2 diabetes.Methods:116 coronary-artery disease and diabetes patients with 186 lesions,were treated with 97 rapamycin eluting stents and 89 paclitaxel eluting stents.The short-term（6 months）outcomes were compared between these 2 groups.Results:The success rate of stent implantation was 100%, major adverse cardiac event（MACE）,during 6 months followup,MACE were 6.78% and 7.02% in the rapamycin eluting stent group and paclitaxel eluting stent group,and there was no significantly difference.Conclusion:The efficacy of rapamycin eluting and paclitaxel eluting stent were similar in coronary heart disease patients with type 2 diabetes.更多还原